

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|-----------------|
| Name of entity | CardieX Limited |
| ABN | 81 113 252 234 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | Craig Cooper |
| Date of last notice | 14 January 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct and indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | 2. C2 Ventures Pty Ltd 3. C2 Ventures Pty Ltd 4. C2 Ventures Pty Ltd 5. C2 Ventures Pty Ltd 6. C2 Ventures Pty Ltd 7. CooperativeHealth, LLC |
| Date of change | 25 October 2021 |

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| No. of securities held prior to change | Direct: 1. 68,000,000 Performance Rights Indirect: C2 Ventures Pty Ltd 2. 177,242,010 FPO 3. 37,500,000 Options at \$0.05 expiring 30 November 2021 4. 234,944 Convertible Notes with face value of \$1 5. 1,500,000 Options at \$0.05 expiring 26 February 2024 6. 4,420,455 Options at \$0.05 expiring 30 November 2021 CooperativeHealth, LLC 7. 36,000,000 Performance Rights |
| Class | See above |
| Number acquired | 1. NIL 2. 20,000,000 FPO 3. NIL 4. NIL 5. NIL 6. NIL 7. NIL |
| Number disposed | 1. NIL 2. NIL 3. 20,000,000 Options at \$0.05 expiring 30 November 2021 4. NIL 5. NIL 6. NIL 7. NIL |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | 1. NIL 2. \$1,000,000 3. NIL 4. NIL 5. NIL 6. NIL 7. NIL |
| No. of securities held after change | Direct: 1. 68,000,000 Performance Rights Indirect: 2. 197,242,010 FPO |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| | 3. 17,500,000 Options at \$0.05 expiring 30 November 2021 4. 234,944 Convertible Notes with face value of \$1 5. 1,500,000 Options at \$0.05 expiring 26 February 2024 6. 4,420,455 Options at \$0.05 expiring 30 November 2021 CooperativeHealth, LLC 7. 36,000,000 Performance Rights |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back | 1. NIL 2. Options Converted 3. Reduction in Options due to Option Conversion 4. NIL 5. NIL 6. NIL 7. NIL |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.